NUCLEOLIN and breast carcinoma: These findings are consistent with the reported results that AS‐based conjugates exhibit significantly lower toxicity toward normal cells than toward breast cancer cells.[30, 31] These results suggested that the designed AS‐2F‐NP exhibited excellent targeting capabilities toward nucleolin‐positive MDA‐MB‐231 cells.